CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
This is a brief. The reporting belongs to CNBC — read the complete story, with full context and credits, at the source.
Read the full story at CNBC ↗cnbc.com
More from the Business desk
Just in
Copper’s plunge could make the AI data-center buildout more painful
Just in
Palo Alto Networks’ stock soars as earnings show AI has upped the stakes for cybersecurity
Just in

Anthropic’s Public Debut Sets Up ‘Experiment’ in Corporate Power
Just in
Tech Stocks Boosted by Cybersecurity Rally
Just in
Anthropic Prices IPO at $83 a Share
